Form 4: Teva CAO Sells 12,300 Shares Under 10b5-1 Plan

Amir Weiss, Teva Pharmaceutical Industries' Chief Accounting Officer, sold 12,300 ordinary shares for a weighted average price of $24.4361 per share.

Summary

• Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries Ltd., reported a sale of company shares.
• The transaction involved the disposition of 12,300 ordinary shares.
• The shares were sold at a weighted average price of $24.4361 per share.
• Sales occurred in multiple transactions ranging from $24.435 to $24.455.
• Following the transaction, Amir Weiss beneficially owns 17,950 ordinary shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider sale under a 10b5-1 plan, which is generally considered neutral in terms of market sentiment as it is not indicative of new information regarding the company's performance or outlook.

Future Outlook

N/A. This filing is an insider transaction report and does not contain forward-looking statements or guidance.

Industry Context

N/A. This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• The sale of shares by a Chief Accounting Officer under a Rule 10b5-1 plan is a routine event and is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors. It represents a pre-planned liquidity event for the executive.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Amir Weiss, Chief Accounting Officer, Insider Sale, Form 4, 10b5-1 Plan, Ordinary Shares, Executive Compensation